Key result
Quinidine demonstrated a plasma half-life of 7.8 hours and 87% oral bioavailability, with higher than predicted concentrations in heart failure patients suggesting impaired elimination.
Why the study?
What are the pharmacokinetic parameters of quinidine in patients with arrhythmias, and how are they affected by heart failure?
Population
51 patients with arrhythmias
Design
Cohort
Authors
Loading...
May warrant quinidine level monitoring in heart failure; leaves open prospective validation of dosing adjustments.
Observational (n=51)
What are the pharmacokinetic parameters of quinidine in patients with arrhythmias, and how are they affected by heart failure?
Quinidine elimination or volume of distribution may be impaired in patients with heart failure, leading to higher than predicted drug concentrations.
Conrad et al. (1977) conducted an observational in Arrhythmias (n=51). Quinidine vs. Patients without heart failure was evaluated on Pharmacokinetic parameters (half-life, volume of distribution, clearance, bioavailability). Quinidine demonstrated a plasma half-life of 7.8 hours and 87% oral bioavailability, with higher than predicted concentrations in heart failure patients suggesting impaired elimination.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: